Rania Baleela: Evaluating Bedside Diagnostics and VICC Outcomes in Hemotoxic Snakebite
Rania Baleela, Associate Professor of Molecular Biology at Faculty of Science, University of Khartoum, shared a post on LinkedIn:
“I am pleased to share our newly published open-access study in Tropical Medicine and Health.
‘Outcomes of venom-induced consumption coagulopathy following snakebite envenoming in Sudan: a cohort study.”
Snakebite envenoming remains an important but under-recognised public health problem in Sudan.
In this hospital-based cohort of 119 snakebite patients, we found that 80.7% developed venom-induced consumption coagulopathy (VICC).
Among patients with VICC:
- 88.5% experienced spontaneous bleeding
- 30.2% developed severe haemorrhage, most commonly intracerebral bleeding
- 29.4% of all patients developed acute kidney injury
- 30.2% of patients with VICC died in hospital
- The 20-minute whole blood clotting test (WBCT20) showed 100% sensitivity for VICC in this cohort, supporting its value as an accessible bedside screening tool, while laboratory confirmation remains important.
These findings highlight the substantial clinical burden of haemotoxic snakebite in Sudan and the urgent need to strengthen snakebite surveillance, access to appropriate antivenom, diagnostic capacity, and evidence-based clinical management.
I am grateful to all co-authors, the patients and their families, and the clinical team at Sinja Teaching Hospital for their contributions to this work.
Read the full open-access article on Springer Nature.”
Title: Outcomes of venom-induced consumption coagulopathy following snakebite envenoming in Sudan: a cohort study
Authors: Abdallateif A. Omer, Abdelsalam M. A. Nail, Burhan A. Mohammed, Rayan Ali Tonga, Tarig Elsammani Eisa, Fatima Altahir, Rania M. H. Baleela, GadAllah Modawe

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 15, 2026, 23:44Pablo César Spada: Prevention of Venous Thromboembolism After Total Hip or Knee Replacement
-
Nov 15, 2026, 23:30Eshal Amir: Factor XI Inhibitors in AFib and Aortic Mortality Trends
-
Nov 15, 2026, 23:19Hamza Bashir: Adding Endovascular Therapy to Anticoagulation Cuts Moderate-to-Severe PTS in Half
-
Nov 15, 2026, 23:06Lanre Tunji-Ajayi: 2 Days of Deliberative Dialogue Hosted by the Network of Rare Blood Disorder Organizations
-
Nov 15, 2026, 23:00Fanny Delettre: Looking Back at Volunteer Blood Donor Friends Day
-
Nov 15, 2026, 20:56Victoria Adedoyin Adisa-Thomas: What I Learned About SCD During My Genetic Counselling Rotation
-
Nov 15, 2026, 20:55Martin Holst Lange: One Step Closer to a Potential New Treatment for Sickle Cell Disease
-
Nov 15, 2026, 20:53Bontha Babu: Health-Related Quality of Life Among Adults with Sickle Cell Disease in India
-
Nov 15, 2026, 20:52Miguel Ángel Herrera Rojas: A First-Line ITP Approach Presented at ASH in 2013 Now Reflected in the 2026 Guidelines